報價延遲最少15分鐘:2026/04/29 02:19 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.8771 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.42/-0.30
|
|
企業價值
109.84M
|
| 資產負債 |
|
每股賬面淨值
1.60
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
33.03M
|
|
每股收益
0.38
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use. |
